CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 949 enrolled
Drug / intervention
flibanserin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00996372
NCT00996372Phase 3Completed
CompareCT.gov

24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States

Sprout Pharmaceuticals, Inc·interventional·Posted Oct 16, 2009·Updated Jun 12, 2014

In Brief

A Phase 3 clinical trial evaluating flibanserin and placebo for Sexual Dysfunctions, Psychological. Completed, enrolled 949 participants across 75 sites.

Detailed Summary

The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunctions, Psychological
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2009
Enrollment StartOct 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.7 years ago

Interventions

flibanserindrug

patients will be randomized to flibanserin or placebo in a double-blind manner

placebodrug

patients will be randomized to flibanserin or placebo in a double-blind manner